Photocure ASA ( (PHCUF) ) has provided an update.
Photocure ASA has granted 100,000 share options to Jane Healy, the newly appointed Vice President and General Manager EMEA, as part of their long-term incentive program. This strategic move aligns with the company’s guidelines for executive remuneration and is expected to strengthen its leadership in the bladder cancer treatment market.
More about Photocure ASA
Photocure ASA, known as The Bladder Cancer Company, specializes in transformative solutions for bladder cancer patients. Their unique technology, which makes cancer cells glow bright pink, has improved health outcomes globally. Headquartered in Oslo, Norway, Photocure is listed on the Oslo Stock Exchange and commercializes its products, Hexvix and Cysview, in multiple international markets.
YTD Price Performance: -18.80%
Average Trading Volume: 484
Technical Sentiment Signal: Strong Buy
Current Market Cap: $150.6M
See more data about PHCUF stock on TipRanks’ Stock Analysis page.